o2h ventures - The o2h Human Health EIS Fund

Fund	Fund Overview
Min Investment	£25,000, there is no maximum investment.
Fund Size	Target Fund size of £10m.
Tax Advantages	If you are a UK tax payer, you may benefit from for S/EIS tax reliefs on investments.
Differentiation	Grassroots working relationships providing early access to deals.
Diversification	We will typically use your subscription to build a Portfolio of 5-10 unquoted and/or AIM-listed companies.
Liquidity	Capital is returned to you only when we are able to sell the shares in your portfolio companies.
Expected Exit	3-7 years. o2h will seek to exit investments after 3 years to avoid losing S/EIS reliefs. The fund may hold investments longer with a view to achieving a better exit. For similar reasons we may exit businesses earlier than 3 years notwithstanding S/EIS reliefs might be lost.
Speed of Investments	While we will aim to deploy capital within 12 months, we will only invest when we find suitably exciting opportunities, which may on occasion extend this period.
Risks	You should only subscribe if you are able to bear losing your entire investment.

featured in

fund overview

The o2h Human Heath EIS Fund Launch

- Sunil Shah, CEO, o2h ventures

Therapeutics, or coming up with next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.

Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community.
Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers.

Request Prospectus

EIS fund benefits

The Enterprise Investment Scheme is a government-backed initiative designed to encourage investment into unquoted and/or AIM-listed companies. It offers generous incentives in the form of tax reliefs, to investors who are prepared to take on the risks of this kind of investment.

Income Tax Relief

Loss Relief

Capital Gains tax(CGT) Relief

CGT Reinvestment Relief

Inheritance Tax(IHT) Relief

*Tax relief depends on an individual’s circumstances and may change in the future.

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

*Tax relief depends on an individual’s circumstances and may change in the future.

about us

The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.

our team See All

Sunil Shah

Chief Executive Officer

Sunil's Biography

Sunil Shah

Chief Executive Officer

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

Prashant Shah

Director

Prashant's Biography

Prashant Shah

Director

A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.

Andy Morley

Chief Scientific Officer

Andy's Biography

Andy Morley

Chief Scientific Officer

Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry.

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary's Biography

Gary Pitts

Compliance Consultant, Tetractys Limited

Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland.Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market.

See All

independent reviews

MICAP – MI Capital Research

Allenbridge – Research Center

target areas

Biotech

Enablers

Oncology / Immunoncology

Anti-ageing

Neuroscience

Anti-Infectives

Genomics / DNA

Small Molecules

Biologics

Digital Therapeutics

recent investments

see all

The o2h human health EIS knowledge intensive fund

The o2h human health SEIS fund

EIS fund benefits

*Tax relief depends on an individual’s circumstances and may change in the future.